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      1.INTRODUCTION 
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1.1. Definition 
Sarcopenia is an age-related syndrome characterised by progressive and generalised 
loss of skeletal muscle mass and strength. It contributes to the risk of physical frailty, 
functional impairment in older people, poor health-related quality of life and premature death 
(1). The term is from Greek σάρξ sarx, "flesh" and πενία penia, "poverty". 
 
1.2. Classification 
 
The Aging in Motion Coalition (AIM) has announced that the Centers for Disease 
Control and Prevention has established an ICD-10-CM code for sarcopenia, so that it can be 
recognized for separate reporting and data collection. The code, M62.84, has been available 
for use by the medical community since October 1, 2016 (2). 
 
Sarcopenia can be considered ‘primary’ (or age-related) when no other cause is 
evident but ageing itself, while sarcopenia can be considered ‘secondary’ when one or more 
other causes are evident (Table 1) (3). 
 
Table 1. Sarcopenia categories by cause 
Primary sarcopenia 
Age related sarcopenia No other cause except ageing 
Secondary sarcopenia 
Activity related sarcopenia Can result from bed rest, sedentary lifestyle, 
deconditioning or zero gravity conditions 
Disease related sarcopenia Associated with advanced organ failure, 
inflammatory disease, malignancy or endocrine 
disease 
Nutrition related sarcopenia Results from inadequate dietary intake of 
energy and/or protein, as with malabsorption, 
gastrointestinal disorders or use of medications 
that cause anorexia 
 
   
European Working Group on Sarcopenia in Older People (EWGSOP) suggests a conceptual 
staging as ‘presarcopenia’, ‘sarcopenia’ and ‘severe sarcopenia’.  
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The ‘presarcopenia’ stage is characterised by low muscle mass without impact on 
muscle strength or physical performance. This stage can only be identified by techniques that 
measure muscle mass accurately and in reference to standard populations. The ‘sarcopenia’ 
stage is characterised by low muscle mass, plus low muscle strength or low physical 
performance. ‘Severe sarcopenia’ is the stage identified when all three criteria of the 
definition are met (low muscle mass, low muscle strength and low physical performance). 
Recognising stages of sarcopenia may help in selecting treatments and setting appropriate 
recovery goals (3). 
 
Table 2. Stages of sarcopenia 
Stage Muscle mass Muscle strength Performance 
Presarcopenia ↓ 
  
Sarcopenia ↓ ↓ ↓ 
Severe sarcopenia ↓ ↓ ↓ 
 
1.3. Epidemiology 
 
In order to estimate the prevalence of low muscle mass, sufficiently large samples of 
the general population are required. Techniques for assessing muscle mass in such settings 
include anthropometry, bioelectrical impedance (BIA) and dual energy x-ray absorptiometry 
(DXA). Anthropometric measures can appear to have certain errors in older people (4) . 
 
BIA produces estimates of total fat mass and non-fat mass and has the advantage over 
DXA because of the fact that the equipment used is portable. However it is questioned to what 
extent BIA provides additional information beyond that from anthropometric measurements. 
DXA is able to divide total body mass into estimates of fat mass, bone mass and lean mass 
(which includes muscle tissue and solid organs). DXA has the advantage that its estimates can 
be restricted to an area of the body, such as the arms and legs and hence avoid measuring the 
lean mass of the solid organs. Cut-points for DXA have typically come from young adult 
values, specifically two standard deviations (SDs) below the sex-specific young adult mean 
  or 
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appendicular lean mass (ALM) divided by height squared. Example cut-points are 7.23 kg / 
m2 in males and 5.67 kg / m2 in females. Applying these cut-points to older populations gives 
estimates of prevalence such as of 20% of those aged 70-79 and 30% of those aged over 80. 
Several measures exist for the measurement of muscle strength. Grip strength has been 
recommended as the most practical method of measuring muscle strength in the clinical 
setting and has been found to correlate physical performance measures in the lower limbs 
(Table 3) (3). Data from the inCHIANTI have been used to produce grip strength cut-points 
two standard deviations below a gender-specific young adult mean, showing a high 
prevalence of weak grip at age 65-74 (5). The most commonly described measure of physical 
performance in the assessment of sarcopenia is gait speed. Gait speed can be assessed in the 
clinical setting by measuring the time taken to walk a set distance, for example 4 m, at usual 
pace (4). 
 
Table 3. Criteria for different study groups 
 
Criteria 
Muscle group Muscle stregth Physical performance 
ESPEN special 
interest groups 
Percentage of muscle 
mass >2 SDs below 
mean in individuals 
aged 18-39 years in 
NHANES III cohort 
    
 
               X 
Walking speed <0.8 m/s in 
the 4-min test or reduced 
performance in any 
functional test used for the 
comprehensive geriatric 
assessment 
 
                
European working 
group on sarcopenia 
in older people 
ALM/h2 
Men  ≤ 7.23 kg/m2 
Women ≤ 5.67 kg/m2 
Grip strength 
Men <30 kg 
Women <20 kg 
Gait speed <0.8 m/s 
International 
working group on 
sarcopenia 
ALM 
Men  ≤ 7.23 kg/m2 
Women ≤ 5.67 kg/m2 
 
              X 
Gait speed ≤1 m/s 
Society of 
sarcopenia, cachexia 
and wasting 
disorders 
ALM/h2 of >2 SDs 
below the mean of 
healthy persons aged 
between 20 and 30 
years of the same 
ethnic group 
 
 
              X 
Gait speed ≤1 m/s or 
walking distance <400 m 
during a 6-min walk 
Foundation of NIH 
sarcopenia project 
ALM 
Men <0.789 
Women <0.512 
Grip strength 
Men <26 kg 
Women <16 kg 
 
                         X 
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Both men and women lose strength, with men losing almost twice as much strength as 
women. The loss of lean mass, as well as higher baseline strength, lower baseline leg lean 
mass, and older age, was independently associated with strength decline in both men and 
women (6). Estimates of the prevalence of gait speed below 0.8 m/s vary. A Spanish study 
found that 56% of men and women aged 75 and over fell below this level (4). Data from the 
Boston Area Community Health and Bone Survey showed higher lean mass index in black (p 
= 0.001) and Hispanic (p = 0.06) men when compared with white men after adjustment for 
confounding influences (7). In the Health ABC Study muscle strength was lower in black men 
and women compared to white men and women, despite the higher measures of lean mass 
observed in these groups. Black participants experienced greater declines in muscle strength 
when compared to white participants (p = 0.001) (6). 
 
Auyeung et al. observed a decline in grip strength in Chinese participants that was 
more rapid than that of ASM and gait speed (8).  Over a 2-year period, women experienced a 
10.0% decline, while men experienced a 3.85% decline. When compared to other ethnic 
populations, the rate of decline in muscle strength was much more rapid in Asian populations 
(9). Rates of decline in physical functioning appear to follow a similar pattern as those 
described for muscle strength with the most rapid declines being experienced among Asian 
populations and the most gradual declines shown in white populations (8, 10). 
  
1.4. Etiology 
 
Multiple factors are associated with decreased muscle mass and/or strength in older 
adults. We can divide these factors into primary and secondary (Table 4) (11): 
 
Table 4. Primary and Secondary types of Sarcopenia 
Primary Age related: sex hormones, muscle apoptosis, mitochondrial dysfunction 
 
Secondary Activity related: physical inactivity, disuse, decon ditioning, zero gravity 
Nutrition related: inadequate dietary intake, malabsorption, gastrointestinal 
disorders or medications that cause anorexia 
Endocrine disorder related: obesity, insulin resistance, inflammatory cytokine, 
steroid treatment, abnormal thyroid function 
Neurodegenerative disorder related: stroke, parkinsonism, diabetic neuropathy 
Chronic disease related: malignancy, advanced organ failure 
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The loss of muscle mass and strength is related to the progressive atrophy and loss of 
individual muscle fibres associated with the loss of motor units, and a concomitant reduction 
in muscle ‘quality’ due to the infiltration of fat and other non-contractile material. These age-
related changes in skeletal muscle can be largely attributed to the complex interaction of 
factors that affect neuromuscular transmission, muscle architecture, fibre composition, 
excitation–contraction coupling, and metabolism (12). 
 
Changes in the hormonal and inflammatory settings result in impairment of protein 
synthesis and increased protein degradation. Buildup or ROS (reactive oxygen species) may 
result in mitochondrial dysfunction which impairs muscle respiration and may result in fiber 
deterioration through loss of myonuclei. Changes in expressing myogenic regulatory factors 
may impair the ability of aged muscle to repair damage (13).  
 
It has been stated that alterations may result in a decline in the content and rate of 
production of ATP, which may affect tissue function, contribute to the aging process, and also 
lead to several disease states. With aging, ATP content and production decreased by 
approximately 50% in isolated rat mitochondria from the gastrocnemius muscle. However, no 
decline was observed in heart mitochondria. The decline observed in skeletal muscle may be a 
factor in the process of sarcopenia, which increases in incidence with advancing age (14). 
 
In 2004, Larsson and colleagues published the first experimental evidence providing a 
causative link between mtDNA mutations and mammalian aging. They demonstrated that 
mtDNA mutations and deletions are responsible for a progressive decline in respiratory 
function of mitochondrially encoded complexes, that was evident as early as 12 weeks, 
resulting in decreased oxygen consumption and ATP production (15). 
 
1.5. Pathology 
 
Neuron loss is a progressive, irreversible process that increases with age. Age-related 
neurodegeneration may contribute importantly to the effects of age on muscle. Multiple levels 
of the nervous system are affected by age, including the motor cortex, the spinal cord, 
peripheral neurons, and the neuromuscular junction. Testosterone concentrations decline as 
age increase, suggesting that low plasma testosterone levels can cause or accelerate muscle- 
and age-related diseases, as sarcopenia (5). 
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Sarcopenia induces a change in the proportion of skeletal muscle fibers, inducing a 
shift from type II (fast) to type I (slow) fibers as well as preferential loss of type II fibers (16).  
 
Higher levels of inflammatory markers were generally associated with greater 5-year 
decline in thigh muscle area. Most associations, with the exception of soluble receptors, were 
attenuated by adjustment for 5-year change in weight. Higher TNF-alpha and interleukin-6 
soluble receptor levels remained associated with greater decline in grip strength in men. 
Analyses in a subgroup of weight-stable persons showed that higher levels of TNF-alpha and 
its soluble receptors were associated with 5-year decline in thigh muscle area and that higher 
levels of TNF-alpha were associated with decline in grip strength (17). 
 
In recent years, it became evident that in these two muscle wasting disorders specific 
regulating molecules are increased in expression (e.g. members of the ubiquitin-proteasome 
system, myostatin, apoptosis inducing factors), whereas other factors (e.g. insulin-like growth 
factor 1) are down-regulated (18). 
 
1.6. Clinical findings 
 
Beginning as early as the 4th decade of life, evidence suggests that skeletal muscle 
mass and skeletal muscle strength decline in a linear fashion, with up to 50% of mass being 
lost by the 8th decade of life (19). 
 
It is usually accompanied by physical inactivity, decreased mobility, slow gait and 
poor physical endurance which are also common features of the frailty syndrome. 
 
Moreover, aging and physical disability are also related to an increase in fat mass, 
particularly visceral fat, which is an important factor in the development of metabolic 
syndrome and cardiovascular disease (CVD). Therefore, sarcopenia with obesity in the elderly 
may synergistically increase their effect on metabolic disorders, CVD and mortality as well as 
physical disability (5). 
 
Sarcopenia represents a major risk factor for adverse events associated with frailty, 
weakness, falls, immobility, functional decline, and institutionalization. Testosterone is the 
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main anabolic hormone for protein synthesis in skeletal muscle and has been shown to 
promote muscle regeneration via satellite cell activation. Serum testosterone levels decline 
with age in both men and women, and this decline is associated with decreased muscle mass 
and strength, especially in men. Similarly, in females, menopause is associated with a marked 
reduction in estrogen levels and an accelerated decline in muscle mass and strength (20). 
 
Vitamin D reduction has been another clinical finding that was noticed in patients with 
sarcopenia. Even though it is still unclear what effect does vitamin D have on skeletal 
muscles, it has been shown that its supplements, when given to vitamin D deficient patients, 
resulted in improved muscle strength ability and a reduction in falls and fractures (5). 
 
Insulin decreases protein degradation and stimulates protein synthesis. An increase in 
insulin resistance with age could result in inhibition of the nitric oxide cascade which would 
result in a lower absorption of amino acids for protein synthesis (20). Diabetes mellitus is a 
condition that is frequently associated with sarcopenia in the elderly. It promotes the reduction 
in muscle mass and strength through hyperglycemia, obesity, and increased general 
inflammation, all of which are known risk factors for sarcopenia (11). 
 
1.7. Differential diagnosis 
 
Sarcopenia can also be featured in some other syndromes associated with muscle 
waisting. Cachexia has recently been defined as a complex metabolic syndrome associated 
with underlying illness and characterised by loss of muscle with or without loss of fat mass. 
The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid 
retention) or growth failure in children (excluding endocrine disorders). Anorexia, 
inflammation, insulin resistance and increased muscle protein breakdown are frequently 
associated with cachexia (21). 
 
Frailty and sarcopenia overlap. Most frail older people exhibit sarcopenia and some 
older people with sarcopenia are also frail. The general concept of frailty, however, goes 
beyond physical factors to encompass psychological and social dimensions as well, including 
cognitive status, social support and other environmental factors (22). 
 
9 
 
In conditions such as malignancy, rheumatoid arthritis and ageing, lean body mass is 
lost while fat mass may be preserved or even increased. This state is called sarcopenic 
obesity, and thus the relationship between age-related reduction of muscle mass and strength 
is often independent of body mass (23). 
 
1.8. Treatment 
 
Physical activity can be seen as an important factor to reverse or modify the 
development of this condition. Several treatments have been proposed for the treatment of this 
loss of muscle and strength, but there is no doubt that exercise represents the most important 
approach to prevent and treat sarcopenia. There are four types of exercise recommended for 
older adults: aerobic, progressive resistance, flexibility and balance training (24). 
 
Aerobic exercise is a form of  structured physical activity characterized by rhythmic 
and repetitive movements of large muscles, for sustained periods that depends primarily on 
the use of oxygen to meet energy demands through aerobic metabolism. Examples for this 
type of exercise are jogging, swimming, tennis, aerobics, bicycle riding and so on. 
Progressive resistance exercise requires muscles to generate force to move or resist weight, 
with increase in intensity as physical capacity improves. It relies on anaerobic metabolism to 
meet energy demands. Examples are lifting weights, working with resistance bands, pull ups, 
push ups, sit ups and so on. Several studies have shown that, even in elderly, progressive 
resistance exercises increases muscle mass, muscle strength, and muscle power. It can 
attenuate sarcopenia in several ways, such as: improving muscle size and function, reducing 
balance and flexibility problems, and reducing the development of many sarcopenia related 
comorbidities. Its successfulness depends on several factors (intensity, training volume, 
periods of recovery between sets, and frequency of training) (24). 
 
Flexibility exercise is a possibility to move a joint through a whole range of motion. 
Stretches can be static (choose a position, hold stretch, than relax), dynamic (fluid motion, 
example is Tai Chi), active (yoga) or a combination. Balance training is an exercise that 
focuses on helping to maintain stability during daily activities and other exercises, preventing 
falls. It can be static (such as standing on one leg) or dynamic (such as walking a tightrope), 
with hand support as needed. Examples of balance training include tandem walking, standing 
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on heels or toes, walking on compliant surface such as foam matresses, walking backwards 
etc. (24). 
 
After injury, the quiescent stem cells that reside between the basal lamina and 
sarcolemma are activated, proliferate, and replenish the satellite cell pool or fuse and 
differentiate to form multinucleated myofibers. However, little success has been achieved by 
exogenous stem cell delivery. Still, certain stem-cell-based strategies for myofiber 
regeneration have been described (Table 5) (20). 
 
Table 5. Stem-cell-based strategies for myofiber regeneration 
 
Cell type 
 
Description 
 
 
Progress towards 
therapeutic 
potential 
 
Challenges 
Satellite cells Adult stem cells; 
Express Pax7 
transcription factor; 
Necessary for 
proliferation and 
maintenance of muscle 
stem cell pool 
50 years from first 
identification to pure 
cell isolation; 
Surface markers 
identified for satellite 
cell isolation are not 
necessarily reflected 
in human 
physiology; Need for 
optimized isolation 
and more efficient 
expansion 
Very difficult to 
isolate and expand in 
culture; 
Limited engrafment 
efficiency. 
Muscle derived stem 
cells 
Adult stem cells; 
Identified in the 
interstitial space in 
mice; 
Nonadherent cell 
population 
Improve muscle 
regeneration; Can 
expand in vitro up to 
30 passages while 
retaining myogenic 
capacity 
Poor engraftment 
efficiency; 
No functional 
improvement despite 
histological 
improvement. 
Perivascular stem 
cells 
Adult stem cells; 
Found in muscle 
microvasculature 
typically vessel 
associated 
CD146+/NG2+/ALP+; 
Express satellite cell 
markers; 
Assume satellite cell 
position after injection 
Currently ongoing 
phase I/II clinical 
trial for pediatric 
muscular dystrophy; 
Can be cultured up to 
20 passages while 
retaining myogenic 
capacity; Better 
engraftment 
efficiency than 
satellite cells; 
Improve muscle 
function 
Varaible in vitro 
scalability gives 
them a finite culture 
life span 
11 
 
Embryonic stem 
cells 
Pluripotent cells 
isolated from inner 
cell mass of blastocyst 
Generation of large 
quantities in vitro is 
possible; 
Engraftment ability 
has been 
demonstrated in 
murine models 
Difficult to 
recapitulate the 
skeletal muscle 
lineage in vitro; 
Potential 
immunologic 
mismatch; Ethical 
concerns 
Induced pluripotent 
stem cells (iPSC) 
Genetically 
reprogrammed somatic 
cells inducing a 
pluripotent state 
Generation of Pax7 + 
iPSCs is possible; 
Genertion of 
functional, human 
skeletal myogenic 
progenitors has been 
accomplished; 
Promote skeletal 
muscle regeneration 
and functional 
improvement 
Requirement for 
genetic correction; 
Risk of tumor 
generation 
 
 
 
Pharmacological approaches to muscle regeneration have traditionally focused upon 
the delivery of anti-inflammatory drugs, steroids, hormones, and growth factors, for example. 
These approaches may hold promise in reverting the functional decline of sarcopenia or 
improving outcomes, but they do not specifically target myogenesis or directly affect the 
restoration tissue function. There is evidence that changing the environment of aged myogenic 
progenitor cells can promote skeletal muscle regeneration. Moreover, clinical evidence 
indicates that mother nature's ideal microenvironment, healthy ECM in the form of a biologic 
scaffolds, promotes myogenesis in patients with volumetric muscle loss (Table 5) (20).  
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1.9. Prognosis 
 
Due to the complex etiology of sarcopenia, finding an effective treatment will require 
a multidisciplinary approach. Ultimate goal should be to identify dietary and exercise 
strategies, lifestyle changes and treatments that can prevent or delay the onset of sarcopenia 
(5). 
 
Identification of the role of cytokines and small molecules, cellular metabolism, and 
endocrine-related changes have helped gain a better understanding of what causes sarcopenia 
and how it progresses. Regenerative medicine strategies, such as the use of an acellular, 
inductive approach that tailors the microenvironment and considers the many cell types 
involved in efficient skeletal muscle regeneration, could provide a promising alternative to 
traditional therapies including stem cell delivery, pharmacological treatment and physical 
rehabilitation. Combining these approaches might help in providing us with improved 
prognosis and better outcomes in patients with age-related muscle loss (20). 
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2. OBJECTIVES 
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The aim of this study was to translate the SarQoL® into Croatian language and 
develop a sarcopenia-specific quality of life questionnaire (SarQoL, Sarcopenia Quality of 
Life) designed for community-dwelling elderly subjects aged 65 years and older. Also, after 
succeeding in translating this questionnaire, we will present the results that we got through 
seven domains, finally proving our hypothesis that sarcopenia in elderly people indeed does 
reduce the quality of life. 
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 3. MATERIALS AND METHODS 
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3.1. Research definition 
 
According to its specific structure, this is a cross sectional type of research, which is 
also one of those included in the category of observational researches. 
 
3.2. Participants 
 
We used the definition of the European Working Group on Sarcopenia in Older People 
(EWGSOP) as criteria for diagnosing sarcopenic subjects. Subjects, aged 65 years and 
older, were recruited in an outpatient clinic in the University Hospital of Split. In total 51 
patient participated in our research by filling out the given Croatian version of SarQoL 
questionnaire without any difficulties in understanding the given questionnaire. 
 
Sarcopenia was defined as follows: 
– An appendicular lean muscle mass/height2 (SMI) <5.5 kg/m2 for women and <7.26 kg/m2 
for men assessed by Dual-energy X-ray absorptiometry. 
– A muscle strength <20 kg for women and <30 kg for men assessed by a hydraulic hand 
dynamometer OR physical performance: ≤8 points for the Short Physical Performance Battery 
(SPPB) test. 
 
Inclusion criteria included age ≥65 years and Croatian maternal language. Exclusion 
criteria were amputated limb and BMI above 30 kg/m2. 
 
3.3. Research venue 
 
The research took place in the Department of Immunology and Rheumatology of the 
Clinic for Internal diseases in the University Hospital of Split. 
 
3.4. Methods of acquiring and processing data 
 
For acquiring the neccessary data, I first performed a thorough and careful translation 
of the official SarQoL questionnaire in English language into Croatian language. This first 
version of the questionnaire was submitted to a Croatian linguist to ensure that it was free of 
any spelling or linguistic errors. 
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This questionnaire includes 55 items translated into 22 questions rated on a 4-point 
Likert scale. In view of observing the participants filling out the materials, the SarQoL was 
easy to complete, independently, in 10 min.  
 
These 55 items that composed the SarQoL questionnaire were allocated to their 
respected domains. In total 7 domains were formed. The domains are the following ones: 
Physical and mental health, Locomotion, Body composition, Functionality, Activities of daily 
living, Leisure activities and Fears. Along with every patient's filled questionnaire, we also 
marked gender and age of each one of them, for later comparative purposes. 
 
All of the data was later on inserted into the Microsoft Excel Programme, where it was 
sorted out as a table, with all the data being ready for use and interpretation of the upcoming 
results. 
 
3.5. Statistical Analysis 
 
In the empirical part of this thesis, by using quantitative methods, the quality of life in 
examined patients with a diagnosis of sarcopenia was tested. Data was collected by 
undertaking the SarQoL survey questionnaire among patients aged older than 65 years with a 
diagnosis of sarcopenia. By using chosen statements, a quality of life scale was formed. The 
scale ranges from 0 to 100, in which the value of 0 presents complete nonfunctionality, while 
the value of 100 presents a full funcionality of a healthy person. We used methods of 
graphical and table presentations, t-test, chi-square test, Wilcoxon's test for one independent 
sample and also correlational analysis. The distribution normality was tested by Kolmogorov-
Smirnov test. Analysis was performed in statistical programme STATISTICA 12 (Licensed 
by University of Osijek). Conclusions were brought with a significance level of 5% . Testing 
of differences between the quality of life domains amongst male and female patients is tested 
with Mann-Whitney U test. 
 
3.6. Ethical Approval 
 
The Ethical Committe of the University Hospital of Split gave the approval for 
conducting this research. 
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4. RESULTS 
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Table 6. Gender and age of study participants 
       F      M P 
Gender n (%) 30 (58.8) 21 (41.2) 0.208* 
Age average (SD) 70.4 (3.1) 70.7 (3.4) 0.734 † 
 
* chi square test 
† t-test 
 
Among the 51 patient, that participated in this research, there were 9 female patients 
more than male patients. Chi square test did not show any differences in prevalence according 
to gender (p=0.208). 
Female gender patients in the sample are in average for 0.3 years (quartal) younger in 
compare to the patients of male gender. Testing has not confirmed any stastically significant 
difference (p=0.734) (Table 6). 
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Figure 1. Physical and mental health domain among female and male participants (0-100) 
The Physical and mental health domain among the examined female participants 
varied in a range from 0 to 80, while amongst male participants it varied in a range between 
20 to 60. In both gender groups, the highest number of participants appeared in the range from 
20 to 40. Results showed 14 female and 11 male participants in this range (Figure 1). 
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Figure 2. Locomotion domain among female and male participants (0-100) 
Locomotion among examined female patients varied from 0 to 80, and most appeared 
in the range from 50 to 80. While among male patients it varied in a range from 50 to 90, with 
most appearing in the range from 50 to 60 (Figure 2). 
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Figure 3. Body composition domain among female and male participants (0-100) 
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Body composition among the largest number of examined participants of both genders 
varied from 30 to 40. Results showed 19 female and 11 male participants presenting with this 
range (Figure 3). 
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Figure 4. Functionality among female and male participants (0-100) 
Functionality among female patients varied in a range of 5 to 55, while among the 
male patients it varied in a range of 30 to 55. Results showed that most of the female and male 
participants appear to be in the range of 40 to 45 (Figure 4). 
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Figure 5. Activities of daily living among female and male participants (0-100) 
Activites of daily living among observed female patients varied in a range of 0 to 80, 
while among observed male patients it varied in a range from 40 to 70. Most female 
participants presented in the range of 50 to 60. Also, most male participants presented in the 
range of 50 to 60 (Figure 5). 
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Figure 6. Leisure activities domain among female and male participants (0-100) 
Leisure activites in both genders varied in a range of 0 to 60. Most of the female 
participants appeared to be in a range from 50 to 60, while most male participants appeared to 
be in ranges from 20 to 30 and from 50 to 60 (Figure 6). 
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Bivariate Distribution: GENDER x Fairs
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Figure 7. Fear domain among female and male participants (0-100) 
We counted a number of 17 male patients saying that they had fear, that due to their 
current status, they would not be able to do certain activities, while on the other side 25 
female patients admited to have fear of being tired after performing activities (Figure 7). 
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Table 8. Correlation between Quality of Life Domains amongst female participants 
 
Physical 
and 
mental 
health 
Locomotion 
Body 
composition 
Functionality 
Activities 
of daily 
living 
Leisure 
activities 
Fears 
Physical  and 
mental health 
1 
      
p= --- 
      
Locomotion 
0.28 1 
     
p=.070 p= --- 
     
Body 
composition 
-0.02 0.31 1 
    
p=.465 p=.050 p= --- 
    
Functionality 
0.24 0.49 0.05 1 
   
p=.105 p=.004 p=.399 p= --- 
   
Activities of 
daily living 
0.33 0.86 0.10 0.49 1 
  
p=.043 p=.000 p=.624 p=.004 p= --- 
  
Leisure 
activities 
0.25 0.66 0.29 0.46 0.70 1 
 
p=.095 p=.000 p=.065 p=.006 p=.000 p= --- 
 
 
Fears 
 
-0.07 -0.47 -0.16 -0.56 -0.49 -0.54 1 
p=.367 p=.005 p=.204 p=.001 p=.004 p=.001 p= --- 
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It has been established that there is an existence of correlation amongst the statements 
(where the empirical p-value does not go above 0.05). This is a case of positive correlation  on 
all statements, except „Fears“, while negative correlation shows us that „fear of feeling tired 
after these activities“ will be substituted with „fear that you might not be able to (do some 
activity)“ outcome of quality of life (Table 8). 
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Table 9. Correlation between Quality of Life Domains amongst male participants 
  
Physical 
and mental 
health 
Locomotion 
Body 
composition 
Functionality 
Activities 
of daily 
living 
Leisure 
activities 
Fears 
Physical and 
mental health 
 
1 
      
p= --- 
      
Locomotion 
 
0.10 1 
     
p=.210 p= --- 
     
Body 
composition 
 
-0.09 0.17 1 
    
p=.0.385 p=.246 p= --- 
    
Functionality 
 
-0.25 0.21 -0.30 1 
   
p=.141 p=.165 p=.092 p= --- 
   
Activities of 
daily living 
 
-0.16 0.19 0.23 0.21 1 
  
p=.255 p=.203 p=.156 p=.180 p= --- 
  
Leisure 
activities 
 
0.12 0.02 -0.45 0.05 -0.10 1 
 
p=.295 p=.146 p=.020 p=.414 p=.336 p= --- 
 
Fears 
 
0.31 -0.16 -0.38 -0.03 -0.02 0.56 1 
p=.086 p=.242 p=.045 p=.456 p=.473 p=.004 p= --- 
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Correlation amongst Quality of Life domains in male participants showed us that 
positive correlation was established only for „Fears“ (Table 9). 
 
Table 10. Results of domain testing and its differences in female and male participants 
 
 
 
  
  F me(IQR) † P M me(IQR) † P 
     Qualitiy of life      
Physical and mental health 41 (35.4-47.9) <0.001* 40 (35.4 - 43.8) <0.001* 
Locomotion 63 (51.9-70.4) 0.001* 67 (59.3 - 70.4) <0.001* 
Body composition 34 (33.3-50.0) 0.001* 34 (33.3- 50.0) 0.003* 
Functionality 44 (41.7-50.0) <0.001* 41 (38.2 - 45.1) <0.001* 
Activities of daily living 57 (50.0-60.0) 0.033* 56 (52.2 -58.9) <0.001* 
Leisure activities 
50 (25.0–
50.0) 
0.505* 25 (25.0-50.0) 0.031* 
     Fears         
   That you might not be able to 4 (13.8) 
<0.001 
17 (81.0) 
 0.007 
  
    Of feeling tired after these   
activities 
25 (86.2) 4 (19.0) 
 
 
  
  
 
 
* Wilcoxon's test for one independent sample 
† Me(IQR) - median (IQR Q1 – Q3 ;  interquartil) 
    F-female, M-male 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
  
    
 
   
After the performed testing, it has been established that there is a higher level of 
Locomotion (p<0.001) and a higher level of Activities of daily living (p<0.001) amongst 
female patients. Leasure activities has moderate quality (p=0.505), while Physical and mental 
health (p<0.001), Body composition (p<0.001), and Functionality (p<0.001) have a low level 
of development. The indicator of life quality, Fear, in the form of „Fear of feeling tired after 
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certain activities“ statement, is statistically by far most common among female patients 
(p<0.001) (Table 10). 
 
Among male patients, there is a high level of developed Locomotion (p<0.001) and 
Activities of daily living (p<0.001). Physical and mental health (p<0.001), Body composition 
(p=0.003), Functionality (p<0.001) and Leisure activities (p=0.031) are on a low level of 
development. The indicator of life quality, Fear, in the form of „that you might not be able to 
do“ statement is statistically ,with significance, most common among male patients (p=0.007) 
(Table 10). 
 
 
Table 11. Differences between quality of life domains according to gender of participants 
  F M P 
Qualitiy of life     
Physical and mental health 41 (35.4-47.9) 40 (35.4 - 43.8) 0.923* 
Locomotion 63 (51.9-70.4) 67 (59.3 - 70.4) 0.135* 
Body composition 34 (33.3-50.0) 34 (33.3- 50.0) 0.713* 
Functionality 44 (41.7-50.0) 41 (38.2 - 45.1) 0.054* 
Activities of daily living 57 (50.0-60.0) 56 (52.2 -58.9) 0.871* 
Leisure activities 50 (25.0–50.0) 25 (25.0-50.0) 0.421* 
Fears 
Fear that you might not be able to 
  
4 (13.8) 
  
17 (81.0) 
  
<0.001 † 
 Fear of feeling tired after these activities 25 (86.2) 4 (19.0) 
* Mann-Whitney U test 
† chi square test 
 
By testing the differences between the quality of life domains there has not been an 
established difference (p>0.05) for any of the indicators, except of Fear, where male patients 
were showed statistically more common with „Fear that you might not be able to“ , while 
female patients most commonly showed to have „Fear of feeling tired after these activities“ 
(p<0.001) (Table 11). 
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5. DISCUSSION 
32 
 
In the present study, we report the development of the first specific, self-administrated 
sarcopenia-related quality of life questionnaire, the SarQoL questionnaire. This questionnaire 
includes 55 items translated into 22 questions rated on a 4-point Likert scale. In view of the 
pretest, the SarQoL is easy to complete, independently, in around 10 minutes.  
 
Sarcopenia is associated with the development of physical disability, with nursing 
home admission, depression, hospitalisation, many co-morbidities, poor physical 
performance, functional decline, falls and with short- and long-term mortality in hospitalised 
patients (25). 
 
In 2012, Kull et al. (26) found a reduced quality of life in two domains (i.e. physical 
function and vitality) of the SF-36 questionnaire in sarcopenic subjects. Two other studies 
found that sarcopenic subjects presented poorer general health and physical functioning scores 
(27) and presented significantly more problems of mobility, self-care, usual activity and 
anxiety than non-sarcopenic subjects (28). Other studies showed an indirect association 
between sarcopenia and quality of life with a significant correlation between reduced grip 
strength, one of the components of sarcopenia, and reduced quality of life in the domains of 
physical functioning and general health (29). 
 
After the performed testing in our research it has been established,and presented in 
Table 10, that there is a higher level of Locomotion (p<0.001) and a higher level of Activities 
of daily living (p<0.001) amongst female patients. Leasure activities has moderate quality 
(p=0.505), while Physical and mental health (p<0.001), Body composition (p<0.001), and 
Functionality (p<0.001) have a low level of development. 
The indicator of life quality, Fear, in the form of „Fear of feeling tired after certain activities“ 
statement, is statistically by far most common among female patients (p<0.001), showing us 
that sarcopenia aside of impacting every day life activities, can also impact ones mental 
status, causing fears. 
 
Among male patients, there is a high level of developed Locomotion (p<0.001) and 
Activities of daily living (p<0.001). Physical and mental health (p<0.001), Body composition 
(p=0.003), Functionality (p<0.001) and Leisure activities (p=0.031) are on a low level of 
development. The indicator of life quality, Fear, in the form of „that you might not be able to 
do“ statement is statistically ,with significance, most common among male patients 
33 
 
(p=0.007), showing us that males, as well as females, also encounter certain impacts on their 
mental status. 
 
Such a tool, like this questionnaire, could enhance the accuracy of assessments of 
well-being and physical function, psychological and social implications of sarcopenic 
subjects. With the future expected development of interventions targeting sarcopenia, this tool 
will also be useful to measure the effectiveness and relevance of these new therapeutic 
strategies. 
 
However, for an even more precise analysis, we did encounter certain limitations. In 
compare to some more detailed researches, such as the one Beaudart et al. did in 2016, we see 
that they used a much larger pool of participants, in compare to our 51 patient, which could 
have been limiting perhaps in some manner. And along with that, they included sarcopenic as 
well as non-sarcopenic participants. They compared the score of the SarQoL® between 
sarcopenic and non-sarcopenic subjects using a logistic regression after adjustment for 
potential confounding variables. Internal consistency reliability was determined using 
Cronbach’s alpha coefficient; construct validity was assessed using convergent and divergent 
validities. Test–retest reliability was verified after a two-week interval using the intra-class 
correlation coefficient (ICC). At last, floor and ceiling effects were also tested (25). 
 
A total of 296 subjects with a median age of 73.3 (68.9–78.6) years were recruited for 
this study. Among them, 43 were diagnosed sarcopenic. After adjustment for potential 
confounding factors, the total score and the scores of the different dimensions of the 
SarQoL® questionnaire were significantly lower for sarcopenic than for non-sarcopenic 
subjects (54.7 (45.9–66.3) for sarcopenic vs. 67.8 (57.3 – 79.0) for non sarcopenic, OR 0.93 
(95%CI 0.90–0.96)). Regarding internal consistency, the Cronbach’s alpha coefficient was 
0.87 (29). The SarQoL® questionnaire was shown to be valid, consistent, and reliable and can 
therefore be recommended for clinical and research purposes. However, its sensitivity to 
change needs to be assessed in future longitudinal studies (25). 
 
The SarQoL has been shown to be comprehensible by the target population in our 
research. Investigations are now required to test the psychometric properties of this 
questionnaire in the future. 
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6. CONCLUSION 
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1. The SarQoL questionnaire was translated successfully, and was understood and solved 
by patients without difficulties.  
 
2. The obtained results showed us that sarcopenia decreases the quality of life and causes 
difficulties in every day life for patients that are diagnosed with sarcopenia.  
 
3. Along with causing difficulties in every day activities, it has also been noticed that all 
patients with sarcopenia, that participated in this research, experienced also some form 
of fear.  
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 8. SUMMARY 
 
41 
 
Objectives: The aim of this study was to translate the official Sarcopenia Quality of 
Life questionnaire into Croatian language so that it is understandable for patients to answer it, 
after which we obtained the answers to assess further on how sarcopenia affects their lives 
through 7 different domains. 
 
Materials and methods: The translated SarQoL questionnaire was given to 51 
patient, all of whom were older than 65 and had a diagnosis of sarcopenia according to the 
European Working Group on Sarcopenia in Older People (EWGSOP). Diagnoses were 
verified by medical record review collected from archives of the Department of Clinical 
Immunology and Rheumatology, University Hospital Split. 
 
Results: After the performed testing it has been established that there is a higher level 
of „Locomotion“ (p<0.001) and a higher level of „Daily living activities“ (p<0.001) amongst 
female patients. „Leisure activities“ has moderate quality (p=0.505), while „Physical and 
mental health“ (p<0.001), „Body composition“ (p<0.001), and „Functionality“ (p<0.001) 
have a low level of development. On the other hand, among male patients, there is a high 
level of developed „Locomotion“ (p<0.001) and „Daily living activities“ (p<0.001). However, 
„Physical and mental health“ (p<0.001), „Body composition“ (p=0.003), „Functionality“ 
(p<0.001) and „Leisure activities“ (p=0.031) are on a low level of development. Male patients 
were showed statistically more common with „Fear that you might not be able to“ , while 
female patients most commonly showed to have „Fear of feeling tired after these activities“ 
(p<0.001). 
 
Conclusions: The SarQoL questionnaire was translated successfully, and was 
understood and solved by patients without difficulties. The obtained results showed us that 
sarcopenia indeed decreases and causes difficulties in the quality of every day life for patients 
that are diagnosed with sarcopenia. 
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9. CROATIAN SUMMARY 
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Naslov: Prijevod i validacija Upitnika o kvaliteti života kod ljudi sa sarkopenijom 
 
Ciljevi: Prevesti službeni SarQoL upitnik na hrvatski jezik kako bi bio razumljiv za 
pacijente koji ga ispunjavaju u svrhu istraživanja, a nakon čega ćemo iskoristiti dobivene 
odgovore te ih provesti kroz 7 domena kako bi ustvrdili kako sarkopenija utječe na kvalitetu 
života. 
 
Materijali i metode: U ispunjavanju prevedenoga SarQoL upitnika je sudjelovao 51 
pacijent, koji je imao/la najmanje 65 godina te koji je imao/la dijagnozu sarkopenije prema 
pravilima koje nalaže Europska radna skupina za sarkopeniju kod osoba starije dobi 
(EWGSOP). Dijagnoze sarkopenije su ovjerene provjerom medicinskih zapisa iz arhive 
Odjela kliničke imunologije i reumatologije, KBC Split. 
 
Rezultati: Nakon provedenog testiranja utvrđeno je da među pacijenticama postoji 
viša razina lokomotornosti (p<0,001) i aktivnosti dnevnog življenja (p<0,001). Ležerna 
aktivnost je umjereno kvalitetna (p=0,505), dok je fizičko i mentalno zdravlje (p<0,001), 
sastav tijela (p<0,001), te funkcionalnost (p<0,001) na niskoj razini razvijenosti. Među 
muškim pacijentima  postoji visoka razina razvijenosti  lokomotornosti (p<0,001), te 
aktivnosti dnevnog življenja (p<0,001). Ipak, fizičko i mentalno zdravlje (p<0,001), sastav 
tijela (p=0,003), funkcionalnost (p<0,001) i ležerne aktivnosti (p=0,031) su na niskoj razini 
razvijenosti. Statistički su muški pacijenti izrazili strah najčešće pod izjavom “Imam strah 
kako neću moći izvršiti neku radnju”, dok su pacijentice najčešće birale tvrdnju “Strah me 
osjećaja umora nakon obavljanja tih navedenih radnji”. 
 
Zaključci: SarQoL upitnik je uspješno preveden te je bio razumljiv i rješen bez 
ikakvih problema od strane pacijenata koji su sudjelovali. Dobiveni rezultati su nam pokazali 
kako sarkopenija uistinu stvara poteškoće i umanjuje kvalitetu svakodnevnog života 
pacijentima koji su dijagnosticirani sa sarkopenijom. 
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